Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Total Employee Number:
522Description
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.83 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.72 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.46 | |||||
Beneish M-Score | -0.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.5 | |||||
3-Year EBITDA Growth Rate | 6.8 | |||||
3-Year EPS without NRI Growth Rate | 43.8 | |||||
3-Year FCF Growth Rate | -112.9 | |||||
3-Year Book Growth Rate | 5.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -66.77 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 1.09 | |||||
9-Day RSI | 6.31 | |||||
14-Day RSI | 13.86 | |||||
3-1 Month Momentum % | 19.71 | |||||
6-1 Month Momentum % | 4.05 | |||||
12-1 Month Momentum % | 64.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.99 | |||||
Quick Ratio | 16.99 | |||||
Cash Ratio | 16.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.6 | |||||
Shareholder Yield % | -0.57 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -226.58 | |||||
Net Margin % | -39.66 | |||||
EBITDA Margin % | -212.94 | |||||
FCF Margin % | -236.25 | |||||
OCF Margin % | -227.51 | |||||
ROE % | -5.87 | |||||
ROA % | -4.56 | |||||
ROIC % | -118.02 | |||||
3-Year ROIIC % | 26.66 | |||||
ROC (Joel Greenblatt) % | -180.39 | |||||
ROCE % | -28.76 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 16.61 | |||||
PB Ratio | 2.34 | |||||
Price-to-Tangible-Book | 2.34 | |||||
EV-to-EBIT | -4.75 | |||||
EV-to-EBITDA | -5.05 | |||||
EV-to-Forward-EBITDA | -4.11 | |||||
EV-to-Revenue | 10.75 | |||||
EV-to-Forward-Revenue | 22.55 | |||||
EV-to-FCF | -4.59 | |||||
Price-to-GF-Value | 0.97 | |||||
| Price-to-Net-Current-Asset-Value | 2.86 | |||||
| Price-to-Net-Cash | 3.04 | |||||
Earnings Yield (Greenblatt) % | -21.05 | |||||
FCF Yield % | -14.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 2,966.259 | ||
| EPS (TTM) (MXN) | -13.413 | ||
| Beta | 0.1339 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 51.58 | ||
| 14-Day RSI | 13.86 | ||
| 14-Day ATR (MXN) | 11.800853 | ||
| 20-Day SMA (MXN) | 565.6175 | ||
| 12-1 Month Momentum % | 64.09 | ||
| 52-Week Range (MXN) | 309 - 655 | ||
| Shares Outstanding (Mil) | 102.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beam Therapeutics Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 96 days | ||
| BEAM-302 Clinical Data | 2026-09-08 07:00 | In 40 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 5 days | ||
| General meeting for 2026 | 2026-06-03 10:30 | 564.61 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-20 10:30 | 460.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 492.25 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-24 08:00 | 604.00 (+0.00%) | ||
| Annual report for 2025 | 2026-02-24 | 604.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-24 | 604.00 (+0.00%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-13 17:15 | 485.00 (+0.00%) |
Show
Entries
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(MEX:BEAM)'s stock price today?
The current price of MEX:BEAM is MXN436.81. The 52 week high of MEX:BEAM is MXN655.00 and 52 week low is MXN309.00.
When is next earnings date of Beam Therapeutics Inc(MEX:BEAM)?
The next earnings date of Beam Therapeutics Inc(MEX:BEAM) is 2026-08-05 Est..
Does Beam Therapeutics Inc(MEX:BEAM) pay dividends? If so, how much?
Beam Therapeutics Inc(MEX:BEAM) does not pay dividend.
Press Release
Articles on Beam Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers